Image

Global Bulbospinal Muscular Atrophy Drugs Market – Industry Trends and Forecast to 2028

  • Pharmaceutical
  • Upcoming Report
  • Jul 2021
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Jul 2021
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Bulbospinal Muscular Atrophy Drugs Market, By Drug Class (5α-Reductase Inhibitors (5-ARIs), Gonadotropin-releasing Hormone (GnRH) Agonists and Others), Drugs (Leuprorelin, Dutasteride and Others), Therapy (Physical Therapy, Occupational Therapy, and Speech Therapy), Treatment (Medication, Supportive Care and Surgery), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics and Others),  Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.

Bulbospinal Muscular Atrophy Drugs Market Market Analysis and Insights : Global Bulbospinal Muscular Atrophy Drugs Market

The bulbospinal muscular atrophy drugs market is expected to gain growth at a potential rate of 12.67% in the forecast period of 2021 to 2028. The rise in research and development activities is the factor responsible for the market growth.

Bulbospinal muscular atrophy (Kennedy’s disease) is a disease under which bulblike structure forms in the lower part of the brain that contains nerve cells controlling muscles in the face, mouth and throat. The condition occurs due to loss of nerve cells in the brain stem and spinal cord, this result in stoppage of messages from brain to muscles for movement. The patients suffering with this disease have difficulty in speaking, standing, walking and controlling their head movements. In worse condition patients can have trouble swallowing and breathing. This disorder mainly affects men and does not occur in females, who are protected by their low levels of testosterone in the body, accounting for the sex-limited inheritance pattern of this disorder.

The rapid rise in incidences of spinal bulbar muscular atrophy is expected to accelerate the market growth in the forecast period of 2021 to 2028. Likewise, initiatives undertaken by various public, as well as non-profit, organizations for creating awareness regarding bulbospinal muscular atrophy also enhance the bulbospinal muscular atrophy drugs market growth. Moreover, the high cost of treatment is projected to restrain the market growth rate whereas the lack of experienced professionals in this field and limited number of drugs available are estimated to challenge the market’s growth.

In addition, the rise in the research and development activities, high adoption of healthcare solutions are likely to create various new opportunities that will impact this bulbospinal muscular atrophy drugs market growth in the forecast period of 2021 to 2028.

This bulbospinal muscular atrophy drugs market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the bulbospinal muscular atrophy drugs market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Bulbospinal Muscular Atrophy Drugs Market Scope and Market Size

Bulbospinal muscular atrophy drugs market is segmented on the basis of drug class, drugs, therapy, treatment, distribution channel and end-users. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of drug class, the bulbospinal muscular atrophy drugs market is segmented into 5α-Reductase Inhibitors (5-ARIs), Gonadotropin-releasing Hormone (GnRH) Agonists and Others.
  • On the basis of drugs, the bulbospinal muscular atrophy drugs market is segmented into leuprorelin, dutasteride and others.
  • On the basis of therapy, the bulbospinal muscular atrophy drugs market is segmented into Physical Therapy, Occupational Therapy, and Speech Therapy.
  • On the basis of treatment, the bulbospinal muscular atrophy drugs market is bifurcated into medication, supportive care and surgery, 
  • Based on route of administration, bulbospinal muscular atrophy drugs market is bifurcated into oral and parenteral.
  • Based on distribution channel the bulbospinal muscular atrophy drugs market is segregated into hospital pharmacy, retail pharmacy and online pharmacy.
  • On the basis of end-users the bulbospinal muscular atrophy drugs market is segmented into hospitals, homecare, specialty clinics and others.

Bulbospinal muscular atrophy drugsMarket Country Level Analysis

Bulbospinal muscular atrophy drugs market is analyzed and market size information is provided by class, drugs, therapy, treatment, distribution channel and end-usersas referenced above.

The countries covered in the bulbospinal muscular atrophy drugs market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America leads the bulbospinal muscular atrophy drugs market due to the increase in the prevalence of bulbospinal muscular atrophy and the unhealthy lifestyle.Asia-Pacific region is expected to expand at a significant growth rate in the forecast period of 2021 to 2028 because of therise in the population and increase in the healthcare awareness and the high adoption of healthcare solutions.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Bulbospinal muscular atrophy drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Global Bulbospinal Muscular Atrophy Drugs Market Share Analysis

Bulbospinal muscular atrophy drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to bulbospinal muscular atrophy drugs market.

The major players covered in the bulbospinal muscular atrophy drugs market report are Novartis AG, F. Hoffmann-La Roche Ltd, BoehringerIngelheim International GmbH, Pfizer Inc., Ionis Pharmaceuticals, Inc., CYTOKINETICS, INC., Regeneron Pharmaceuticals, Inc., Salarius Pharmaceuticals, Inc.,  Leadiant Biosciences, Inc., Abbott, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, AstraZeneca,  Catalyst Pharma, PTC Therapeutics, Natera, Incamong othersamong other domestic and global players. Bulbospinal muscular atrophy drugs market share data is available for global, North America, South America, Europe, Asia-Pacific (APAC) and Middle East and Africa (MEA) separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.


SKU-

Why Choose Us


Frequently Asked Questions